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Cells of myeloid origin, such as microglia and macrophages, act at the crossroads of sev-
eral inflammatory mechanisms during pathophysiology. Besides pro-inflammatory activity
(M1 polarization), myeloid cells acquire protective functions (M2) and participate in the
neuroprotective innate mechanisms after brain injury. Experimental research is making
considerable efforts to understand the rules that regulate the balance between toxic
and protective brain innate immunity. Environmental changes affect microglia/macrophage
functions. Hypoxia can affect myeloid cell distribution, activity, and phenotype. With their
intrinsic differences, microglia and macrophages respond differently to hypoxia, the for-
mer depending on ATP to activate and the latter switching to anaerobic metabolism and
adapting to hypoxia. Myeloid cell functions include homeostasis control, damage-sensing
activity, chemotaxis, and phagocytosis, all distinctive features of these cells. Specific mark-
ers and morphologies enable to recognize each functional state. To ensure homeostasis
and activate when needed, microglia/macrophage physiology is finely tuned. Microglia are
controlled by several neuron-derived components, including contact-dependent inhibitory
signals and soluble molecules. Changes in this control can cause chronic activation or prim-
ing with specific functional consequences. Strategies, such as stem cell treatment, may
enhance microglia protective polarization.This review presents data from the literature that
has greatly advanced our understanding of myeloid cell action in brain injury. We discuss
the selective responses of microglia and macrophages to hypoxia after stroke and review
relevant markers with the aim of defining the different subpopulations of myeloid cells that
are recruited to the injured site. We also cover the functional consequences of chronically
active microglia and review pivotal works on microglia regulation that offer new therapeutic
possibilities for acute brain injury.
Keywords: neuroinflammation, microglia, macrophages, acute brain injury, phenotypical polarization, cell
morphology
CLASSICAL VIEW OF NEUROINFLAMMATION
In the late 19th century, Paul Ehrlich observed that a water-soluble
viable dye injected into the peripheral circulation stained all organs
except the central nervous system (CNS), providing the first indi-
cation that the CNS was anatomically separated from the rest
of the body. The idea that the brain was a unique anatomical
compartment was further confirmed by Edwin Goldman who
Abbreviations: AD, Alzehimer’s disease; ADAM, a disintegrin and metallopro-
teinase domain-containing protein; ADP, adenosine diphosphate; AIM2, absent in
melanoma 2; ASC2, apoptosis-associated speck-like protein containing a CARD 2;
ATP, adenosine triphosphate; BBB, blood–brain barrier; BDNF, brain-derived neu-
rotrophic factor; CC, corpus callosum; CNS, central nervous system; CX, cortex;
DAMPs, danger-associated molecular patterns; DAP12; DNAX activation protein
of 12kDa; EMR1, EGF-like module-containing mucin-like hormone receptor-like
1; GDNF, glial cell-derived neurotrophic factor; GFP, green fluorescent protein;
HIF-1α, hypoxia-inducible factor-1α; HMGB1, high mobility group box 1; Hsp,
heat shock protein; Iba1; ionized calcium-binding adaptor 1; ICAM; intercellular
adhesion molecule; IFN-γ, interferon-γ; IGF-1, insulin-like growth factor-1; IL,
interleukin; iNOS, inducible nitric oxide synthase; LAMP; lysosomal/endosomal-
associated membrane glycoprotein; LPS, lipopolysaccharide; LV, lateral ventri-
cle; µ, microglia; M, macrophage; MBL, mannose-binding lectin; MCA, middle
showed that a dye injected into the spinal fluid did not stain
peripheral tissues. This is of course due to the blood–brain barrier
(BBB) that restricts access of soluble factors to the brain, includ-
ing 98% of antibodies and immune cells. This feature together
with the lack of a lymphatic system, low constitutive levels of
major histocompatibility complex (MHC) class I and II molecules,
local production of suppressive factors, and limited numbers of
cerebral artery; MCP-1, monocyte chemoattractant protein 1 (also known as
CCL2); MCSF, macrophage colony stimulating factor (MCSF); MerTK, Mer recep-
tor tyrosine kinase; MFG-E8, milk fat globule EGF-like factor-8; MHC, major
histocompatibility complex; MSC, mesenchymal stem cells; NCX, sodium cal-
cium exchanger; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B
cells; NLRP, NOD-like receptor protein; NO, nitric oxide; OGD, oxygen-glucose
deprivation; PCR, polymerase chain reaction; PD, Parkinson’s disease; POP1,
pyrin-only protein 1; PRR, pattern recognition receptor; PTP, protein tyrosine
phosphatase; RANTES, regulated upon activation normal T cell expressed and
presumably secreted; rµ, rod microglia; ROS, reactive oxygen species; SCI, spinal
cord injury; STR, striatum; TBI, traumatic brain injury; TLR, toll-like receptor;
TNFα, tumor necrosis factor α; TGF-β, transforming growth factor β; TREM2,
triggering receptor expressed on myeloid cells 2; WBC, white blood cells; WT,
wild type.
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professional antigen-presenting cells drove the concept of the CNS
as an immuno-privileged site (1).
In normal conditions, the presence and trafficking of immune
cells in the brain are negligible. However, we now know that the
brain is far from being an inactive immune organ. It has actually
its own resident immune population, microglia, in addition to the
fact that the BBB can allow active import of immune molecules and
cells. After injury, brain immunity includes a variety of events that
develop non-linearly in response to multiple factors and involve
complex interactions between cells and environmental signals. As
a consequence, in CNS disorders, activation of distinct inflamma-
tory pathways may affect the course of an injury in different and
possibly opposing ways (2).
Cells of myeloid origin, such as microglia and macrophages,
are major actors in brain inflammation, a hallmark of acute brain
injury. Microglia reside in the CNS and actively monitor the
surrounding microenvironment (3). Under physiological condi-
tions, these cells play a variety of roles that go beyond classical
inflammatory activity, including support to synaptic wiring dur-
ing development and monitoring of neuronal firing in the mature
brain, thus contributing to brain homeostasis (4, 5). After an acute
CNS injury, microglia act mainly as a player of the immune sys-
tem. Virtually all CNS disorders involve reactive microglia and
the progression and resolution of many diseases also depend on
microglial activity (6).
Microglia share the theater of their action with blood-borne
macrophages, which infiltrate into the inflamed CNS. Both cell
populations show a range of functional states, with a specific
pattern of receptor expression, molecule production, and mor-
phological feature acquisition. The inflamed environment plays a
major role in the definition of their overall function by providing
stimuli that induce specific phenotypical/functional states.
An open challenge is to properly characterize the roles of
microglia and macrophages in brain injury progression and
resolution. This would help define the milestones for effective
manipulation of brain inflammation, with the specific aim of
favoring its protective arm and boosting innate neuroprotec-
tive mechanisms. This review will look at the latest findings on
inflammation in acute brain injury, specifically addressing the
impact of environmental signals on the function of microglia
and macrophages in injury and neuroprotection. We will specif-
ically discuss (1) the latest view of neuroinflammatory mecha-
nisms, depicting the rationale for focusing on myeloid cell pro-
tective modulation; (2) the ability of the inflamed environment
to drive myeloid cell behavior, particularly their distribution,
expression markers, and morphology; (3) the impact of selec-
tively primed/modulated states of microglia on the exacerbation
or resolution of neurological disorders.
CHANGING THE ANGLE: A NEW VIEW OF
NEUROINFLAMMATION
Data accumulated over the last decade have deeply changed the
general view of inflammation in the CNS. A striking new con-
cept has been that brain immunity, in addition to the well-known
pro-inflammatory actions, can initiate protective mechanisms by
exploiting the bivalent nature of microglia and macrophages.
In vitro experiments indicate that these cells may develop either a
classic pro-inflammatory M1 or an alternative anti-inflammatory
and pro-healing M2 polarization (7). In vivo, microglia and
macrophages appear to acquire intermediate phenotypes, whose
ultimate functions rely on the combination of different polar-
ization markers ranging from M1 to M2 (2, 8). Multiple fac-
tors concur to determine myeloid cell functional states and may
offer a way to therapeutically manipulate myeloid cell activa-
tion. From this viewpoint, microglia and macrophages seem at
the crossroads of several inflammatory mechanisms, through-
out the entire course of brain pathophysiological events. They
can be viewed as in situ expert operators whose timely actions
may contain and resolve brain injury. Experimental research is
now dedicating considerable effort to understanding the rules
that govern brain innate immunity, to implement strategies for
manipulating the innate immune response to favor its protective
functions (9).
In the inflamed CNS, activated microglia and recruited
macrophages present some common features and some distinct
characteristics. Common features include the expression of com-
mon phenotypic markers, the ability to polarize toward M1/M2
phenotypes, the phagocytic behavior, and the ameboid shape
that activated microglia may acquire. Microglia and macrophages,
however, differ in several aspects and recent work has attributed
exclusive features to each of these cell populations. Microglia orig-
inate from primitive hematopoiesis in the fetal yolk sac, take up
residence in the brain during early fetal development, and retain
the ability to proliferate. By contrast, macrophages derive from
granulocyte–monocyte progenitors during both development and
adulthood (6, 10). Microglia have a lower turnover rate than
macrophages: respectively 6 months and 17 h in mice (11). The
activation of microglia depends on ATP/ADP signaling, whereas
macrophages are equipped to maintain viability and function in
hypoxia/ATP loss (3, 10). Finally, only microglia have a rami-
fied morphology, with branches that emerge from the cell body
and communicate with surrounding neurons and other glial cells
(12, 13).
Whether these differences imply different roles in brain injury
progression and repair has yet to be fully determined, though
there is increasing evidence that microglia should be considered
functionally distinct from macrophages (14, 15).
THE HYPOXIC ENVIRONMENT, A MAJOR CUE TO MICROGLIA
AND MACROPHAGE ACTIVATION
After acute brain injury such as stroke, traumatic brain injury
(TBI), subarachnoid, or intracerebral hemorrhage, a series of
neurochemical processes is unleashed and gives rise to a com-
plex pathophysiological cascade that can be viewed as cellular
bioenergetic failure triggered by hypoperfusion (16). Hypoper-
fusion leads to hypoxia, which precedes and causes detrimental
events, such as excitotoxicity, oxidative stress, BBB dysfunction,
microvascular injury,hemostatic activation,post-ischemic inflam-
mation and, finally, cell death (17, 18). All these events contribute
to changing the ischemic environment over time and, conse-
quently, the behavior of microglia and macrophages. Because
hypoxia immediately follows hypoperfusion, it affects the brain
myeloid cell response to injury early. Here, we discuss the effects of
hypoxia on microglia and macrophage behavior and the different
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activations and recruitments of these two populations in an
ischemic environment.
MICROGLIA AND MACROPHAGE BEHAVIOR IN HYPOXIC CONDITIONS
Microglia consume energy in an ATP-dependent manner for their
broad range of activities, including inflammatory mediator pro-
duction (19) and cytoskeleton reorganization (20, 21). Microglia
are thus highly susceptible to energy deficits and local changes
in blood perfusion after acute injury probably affects microglia
reactivity and survival.
Hypoxia induces a time-dependent autophagic cell death in
microglia cultures with increased release of pro-inflammatory
cytokines (IL-8 and TNFα) through the hypoxia-inducible factor-
1α (HIF-1α) dependent pathway (22). HIF-1α is a transcription
factor responsible for the adaptation of cells to low oxygen tension,
for the regulation of glucose metabolism and for cell proliferation
and survival (23, 24). Its expression is induced in the ischemic
brain (25). However, its exact role still needs clarification, as it
has been seen to display either protective or detrimental functions
(26–29).
Unlike microglia, macrophages can switch their metabolism
to anaerobiosis and remain viable in hypoxic/ischemic conditions
(10, 30). Many pathological processes, such as tumors, athero-
sclerosis, and ischemia, involve a low oxygen concentration and
the concomitant presence of macrophages (31). Efforts have been
made to clarify how macrophages adapt to low oxygen concen-
trations. The HIF-1α and nuclear factor κB (NF-κB) families
of transcription factors are major regulators of this adaptation
(31, 32). Myeloid cell-mediated inflammatory response requires
HIF-1α and involves a decrease in the expression of inducible
nitric oxide synthase (iNOS) and reduced production of ATP
by glycolysis (33, 34). Hypoxia can mediate NF-κB activation,
favoring the production of inflammatory cytokines (32), and
hypoxia-induced CXCL12 expression regulates mobilization and
homing of hematopoietic stem and progenitor cells to the ischemic
tissue (35–37).
MICROGLIA AND MACROPHAGE BEHAVIOR IN THE ISCHEMIC BRAIN
LESION
The ischemic environment drives macrophage recruitment,
and this results in the co-presence of infiltrating blood-borne
macrophages and resident reactive microglia in the lesioned
site (12). In experimental brain ischemia/reperfusion injury,
green fluorescent protein (GFP)-expressing microglia studied by
in vivo two-photon microscopy show prolonged resilience to
ischemic conditions by becoming stalled, with reduced dynamic
behavior. As blood perfusion is re-established, microglia recover
their behavior and rearrange the cytoskeleton, acquiring either
a bushy morphology, with multiple short processes around
enlarged cell bodies (38, 39), or a reactive ameboid shape
(21, 40).
When there is no reperfusion, e.g., after permanent ischemia or
TBI, hypoxia may persist beyond the resilience limit of microglia,
causing microglia irreversible damage and death (3). Accord-
ingly, compared to ischemia/reperfusion, injuries with no reper-
fusion cause a larger lesion area depleted of microglia. The
microglia-empty territory is rapidly replenished by round-shaped
CX3CR1-/CD11b+/CD45high+ cells, which are likely to be the
infiltrating macrophage population (8, 41).
As discussed above, macrophages can switch to an anaerobic
metabolism and adapt to hypoxic/ischemic conditions. In exper-
imental stroke models, immune cell infiltration is more evident
after permanent than transient occlusion of the middle cerebral
artery (MCA) (42, 43). A schematic representation of differential
distribution of microglia and macrophages at early stages after
permanent or transient ischemia or TBI is depicted in Figure 1.
FIGURE 1 | Microglia and macrophage distribution over the lesion area
24 h after injury in three different models of acute brain injury. (A) After
transient middle cerebral artery occlusion (tMCAo), the lesion core is
populated by infiltrated macrophages (M) and bushy/ameboid microglia (µ).
The penumbra contains hypertrophic µ. (B) After permanent middle cerebral
artery occlusion (pMCAo) no µ cells are present in the lesion core where
there is high M infiltration. Bushy µ cells surround the lesion core. (C) The
distribution is similar after traumatic brain injury (TBI). M are recruited to the
lesioned tissue close to its lesion edge, while bushy and hypertrophic µ cells
populate more distant areas.
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The metabolic status of the lesioned environment is thus
a major determinant in the recruitment/activation of myeloid
cells in the CNS and in the balance between microglia and
macrophages. The consequences of the specific composition of the
myeloid population still need clarification. Yamasaki et al. recently
compared the transcription profiles of microglia or monocyte-
derived macrophages in a model of experimental autoimmune
encephalopathy. They showed that microglia downregulated meta-
bolic pathways, whereas macrophages displayed active phagocytic
and pro-inflammatory behavior (44). Although this observa-
tion cannot be extended to other injury models, these findings
reinforce the idea that microglia and macrophages have differ-
ent intrinsic properties that govern their specific responses to
environmental signals.
Macrophages engrafted microglia-depleted brain regions in
CD11b-HSVTK mice (45), a model of selective microglia deple-
tion obtained by intracerebroventricular valganciclovir (46, 47). In
this model, macrophages infiltrated within 2 weeks after depletion
and showed microglia-like behavior, extending processes toward
an ATP source. This might indicate that macrophages could pop-
ulate the adult brain and replace microglia in sustain cerebral
homeostasis (45). After a severe acute injury with impairment
of the cerebral blood flow and no reperfusion, brain homeosta-
sis is disrupted and metabolic crisis occurs, leading to massive
death of cerebral cells, including microglia. Macrophages invade
these lesioned regions and become activated. In these conditions,
their role is likely to be different from that of surveying microglia.
At early times, infiltrated round-shaped CD11b/CD45high cells
express M2 polarization markers, while microglia are mostly
located at lesion boundaries with lower expression of polarization
markers (8).
The picture in acute phase of brain injury may not apply
at longer times when other events, such as microglial prolifer-
ation, might define a different balance between microglia and
macrophages. Microglia proliferate starting 72 h after focal brain
ischemia induced with the filament model in mice (48). Microglial
proliferation in the lesioned brain areas is affected by the sever-
ity of injury, being clearly observable after 30 min of transient
ischemia, but only weakly after more severe 60 min of ischemia.
This latter caused wide areas of microglia loss where subsequent
replenishment with fresh microglia was limited (48).
Local proliferation may also be promoted by pericytes, as
recently shown after permanent ischemia (49). In response to
ischemia, pericytes may leave the vessel wall and settle in the brain
parenchyma. Pericyte infiltration occurs specifically in the lesioned
area depleted of microglia cells, reaches its peak 7 days after injury
and is still detectable at 21 days. These infiltrated pericytes express
typical microglia markers, such as Iba1, CD11b, and GAL-3, but
interestingly, they are negative for CD68 and CD45high, these latter
associated with leukocytes (49). Thus pericytes may function as a
local source of microglia, and this may be a potential mechanism
of microglial repopulation of severely injured areas.
The ischemic milieu changes over time, possibly also as a con-
sequence of changes in blood perfusion. Areas with preserved
blood flow soon after ischemia may have defective perfusion at
later times because of the formation of secondary clots. This is
generally referred to as “no-reflow” (50, 51) and may depend on
different mechanisms, such as fibrin deposition and platelet activa-
tion (52–54), or clotting of immune cells in small capillaries (55).
Delayed perfusion deficits can potentially affect microglial activ-
ity and proliferative ability in selected brain areas and shifting the
balance between resident microglia and recruited macrophages.
SURFACE ANTIGENS: THE INTERFACE BETWEEN MYELOID
CELLS AND ENVIRONMENT
The differential behavior of microglia and macrophages in
response to the hypoxic environment suggests intrinsic differ-
ences in the nature of these populations. However, in experimental
research, microglia and macrophages are often referred to as an
unique population, because their study relies on labeling non-
selective surface antigens, which are expressed constitutively or
after activation by either cell types. For some markers different pat-
terns of expression may help distinguish resident from infiltrated
myeloid cells. Here, we discuss the most widely used markers, par-
ticularly murine markers of myeloid cells, providing information
on their interaction with the environment and on the biology of
myeloid cell subtypes.
CONSTITUTIVE MARKERS
CD11b is one of the most commonly used surface markers for
immunostaining microglia/macrophages (8, 56). It belongs to
the integrin family of surface receptors and is covalently bound
to a β2 subunit to form integrin aMb2 (Mac-1, CD11b/CD18),
which is implicated in diverse responses including cell-mediated
killing, phagocytosis, chemotaxis, and cellular activation. CD11b
is upregulated after microglia/macrophage activation and recog-
nizes several ligands including C3 fragments, resulting from com-
plement activation, fibrinogen, intercellular adhesion molecule-1
(ICAM-1), denatured products, and blood coagulation factor X.
With its presence on the membrane surface and its constitutive
expression, CD11b is particularly suitable for studying myeloid
cell morphology in either physiological or pathological conditions
(Figure 2).
Myeloid cells are often labeled by another constitutive marker,
ionized calcium-binding adaptor 1 (Iba1) that provides infor-
mation on their activation and morphology comparable to that
with CD11b (57, 58). Iba1 is a calcium-binding protein specific
for myeloid cells and has a role in bundling actin, in membrane
ruffling and phagocytosis (59).
CD45 is a transmembrane glycoprotein expressed by cells of
hematopoietic origin, except erythrocytes. It is a member of
the protein tyrosine phosphatase (PTP) family. Its intracellu-
lar carboxy-terminal region contains two PTP catalytic domains,
whereas the extracellular region varies widely due to alternative
splicing of exons 4, 5, and 6 (designated as A, B, and C, respec-
tively). CD45 has a role in T- and B-cell signal transduction and in
the adult mouse the expression of selective isoforms depends on
the cell type and activation state. Microglia express low constitutive
levels of CD45 and even after activation they maintain lower levels
of CD45 than circulating/infiltrating leukocytes. CD45 labeling,
therefore, gives a weak signal in microglia that can be exploited
to distinguish resident microglia from infiltrated immune cells
by either immunohistochemistry or flowmetry (8, 40, 60, 61)
(Figure 2).
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FIGURE 2 | CD11b or CD45 label myeloid cells in the mouse brain 24 h
after focal transient ischemia. Left panel: CD11b is commonly used to label
myeloid cells in the mouse brain and provides detailed information on
morphology because it is expressed uniformly on the cell membrane.
Twenty-four hours after focal transient ischemia, different microglia cell types
can be found in the hemisphere ipsi-lateral to the lesion. Bushy microglia (µ)
populate the cortex (penumbra) and rod microglia (rµ) with elongated
morphology are present in the white matter (corpus callosum) and
hypertrophic reactive microglia (reactive µ) populate the striatum, the area
that corresponds to the lesion core. Right panel: CD45 labeling helps
distinguish resident microglia from recruited leukocytes. Microglia have
ramified morphology and pale staining (CD45low), whereas infiltrated
leukocytes (white blood cells, WBC) can be identified by their round-shaped
morphology and strong, well-contrasted staining (CD45high). The elongated
shape of CD45high cells may depend on crawling along vessel walls or their
perivascular location. Bars=100µm, microphotograms modified from Ref.
(40). Neuro-anatomical structures are indicated by CX (cortex), STR (striatum),
CC (corpus callosum), and LV (lateral ventricle).
Isolectin B4 binds α-d-galactosyl residues, which are expressed
on microglia surface and on activated endothelial cells. This
marker labels myeloid cells non-homogeneously and it also
binds to endothelial cells (62). So it cannot be used to label
microglia/macrophages clearly in tissue specimens. Thus, isolectin
B4 is mainly employed to label in vitro microglial cells, giving a
homogeneous staining and a quick immunostaining protocol (63,
64).
The receptor for fractalkine (CX3CR1) is constitutively present
on microglia and is inducible in specific subsets of macrophages.
Its main function in the brain is to support the communica-
tion between microglia and neurons. We discuss below the role
of CX3CR1 and its deletion in different pathological conditions.
Transgenic mice expressing GFP under the promoter of cx3cr1
(cx3cr1GFP/+) are commonly used to visualize microglia in in vivo
(40) and in ex vivo experimental settings (65). Our group has
shown that the expression of GFP in cx3cr1GFP/+ mice helps distin-
guish microglia and infiltrated immune cells at early times (24 h)
after ischemia (40) or TBI (41). Only ramified CD11b positive
cells express GFP, whereas round-shaped cells, positive for CD11b
and CD45high, or CD3 (a marker for lymphocytes) do not. The
first subset of infiltrating macrophages is recruited through CCR
receptors and they do not express CX3CR1. Circulating monocytes
have been divided into two subsets, the classical one expressing the
CCR family receptors and prone to tissue invasion upon recruit-
ment (66–68) and the non-classical subset, positive for CX3CR1.
This latter subset patrols along blood vessel walls and accumulates
in peripheral tissues, such as spleen, lung, and liver (68–70). Non-
classical monocytes are recruited in the brain at later stages after
acute injury, so they are not present at early times, so CX3CR1
positivity can be used as a selective marker for resident microglia
early after injury.
The identification of a unique microglial molecular fingerprint
would facilitate the study of microglia biology and help develop
their therapeutic modulation. Recent gene profiling of murine
CD11b+/CD45low microglia compared to that of Ly6Chigh or
Ly6Clow macrophages showed that there were a number of genes
highly or uniquely expressed by microglia, such as P2ry12, Gpr34,
Mertk, C1qa, Gas6, and Fcrls (71). FACS analysis indicated that
antibodies against P2ry12 or FCRLS stained adult microglia, but
not CD11b-gated myeloid cells isolated from spleen, bone marrow,
and peripheral blood (71). P2ry12 and FCRLS need further vali-
dation, for instance in brain pathologies, but they offer promise as
selective molecular markers for resident microglia.
The genetic profiles of microglia and macrophages have been
recently associated with environmental signals that drive these cell
identities (72). Gene profiling of mouse microglia and peritoneal
macrophages revealed that the cerebral and peritoneal environ-
ments drive different programs of gene expression by differen-
tially activating a common repertoire of enhancers. The activated
enhancer repertoire in turn promotes the expression of secondary
transcription factors that collaborate with PU.1 – the critical tran-
scription factor initiating myeloid cell differentiation – to estab-
lish tissue-specific enhancers, ultimately defining the myeloid cell
identity (72). This study indicates that microglia express high levels
of Cx3cr1 and Nav3, whereas peritoneal macrophages express Lyz2,
Fn1, H2-Eb1, Cebpb, Gata6, and Ciita in a subset-specific manner.
Whether brain-infiltrating macrophages have similar genetic pro-
file to peritoneal ones is still to be determined; however, this study
further demonstrates that microglia and peripheral macrophages
have intrinsic genetic differences and propose the environment as
a major determinant of these differences.
POLARIZATION MARKERS
As mentioned above, after activation the commitment of microglia
and macrophages can be either toxic or protective. Microglia
can affect neuronal function and promote neurotoxicity (73)
through the release of several pro-inflammatory molecules, such
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as IL-1β, TNF-α, proteases, and reactive oxygen species (ROS)
(74). However, under certain circumstances microglia can be neu-
roprotective and promote adult neurogenesis and lesion repair
(75, 76). Microglia can be neurosupportive through several mech-
anisms including glutamate uptake (77), removal of cell debris
(78), and production of neurotrophic factors, such as insulin-like
growth factor-1 (IGF-1) (79), glial cell-derived neurotrophic fac-
tor (GDNF) (80), and brain-derived neurotrophic factor (BDNF)
(81). The dual nature of microglial polarization is similar to
that of macrophages generally referred to as M1 or M2 (82).
According to this classification, macrophages can develop a clas-
sic pro-inflammatory (M1) or an alternative anti-inflammatory
(M2) polarization. Specific environmental signals induce these
different polarization states (7). In particular, stimulation through
toll-like receptor (TLR) ligands and INF-γ induces classical M1
activation, while IL-4/IL-13 stimulation favors the alternative M2
activation (83).
M1 and M2 canonical definitions represent the extreme of
macrophage-polarized states documented in vitro (84). A generally
accepted classification of the microglia/macrophage repertoire of
polarized states indicates one M1 toxic polarization and three M2
polarization subtypes, M2a, M2b, and M2c, each with a specific
function and pattern of marker expression (84). M1 is associated
with phagocytosis, ability to kill pathogens by iron restriction,
phagosome acidification, and ROS release (85–88). M1 pheno-
type markers include CD16, CD32, CD86, MHC II, and iNOS.
M2a-polarized state is associated with immunity against parasites,
recruitment of Th2 cells, tissue repair, and growth stimulation.
This state is marked mainly by the expression of arginase-1, Ym1,
and Fizz (85–95). M2b has either pro- or anti-inflammatory func-
tions and is associated with memory immune response (B-cell
class switch and recruitment of regulatory T cells). High IL-10
expression, MHC II, and co-stimulatory CD86 define the M2b pat-
tern (85–87, 96–100). M2c is involved mainly in scavenging cell
debris, has healing functions, and expresses arginase-1, CD163,
and CD206 (85–87, 89, 90, 95, 100–102). An M0 phenotype has
been recently introduced to indicate a non-polarized state. Adult
microglia cultured with macrophage colony stimulating factor
(MCSF) and TGF-β have a phenotype similar to fresh-cultured
adult microglia and therefore have been defined to as M0 (71).
These antigenic fingerprints for polarization are well mirrored
in some pathological conditions in vivo, including parasite infec-
tions, allergy, and cancer (83). In neurodegenerative disorders,
myeloid cells often present mixed phenotypes indicating their
plastic nature and their ability to acquire multiple phenotypes in
response to environmental signals and time-dependent changes in
the inflammatory milieu (83). As a further element of complex-
ity, some markers are clearly assigned to a specific polarization
state, while others do not clearly belong to one or the other. As an
example MHCII and CD86 may be found in either the M1 or the
M2 phenotype (84). MHCII is involved in antigen presentation to
immune cells and CD86 functions as a co-stimulatory signal for
T-cell activation. It is intriguing that microglia/macrophages act-
ing as antigen-presenting cells are not easily classified as toxic or
protective. Quite possibly T-cell activation needs to be finely tuned
to yield a tolerization state, associated with protective action (103,
104), rather than an aggressive (auto)-immune response. For a
satisfactory definition of myeloid cell polarization in CNS diseased
states, further studies in models of pathology are needed. Events
such as infiltration of leukocytes are important in orchestrating
polarization, making the in vivo studies far more instructive than
in vitro models, which cannot reproduce the complete network of
recruited/activated cells.
REACTIVE MARKERS
The activation of microglia/macrophages is driven by many fac-
tors, including cytokines, chemokines, released degradation prod-
ucts, and extravasated molecules. Specific responses to these fac-
tors have been thoroughly reviewed elsewhere (105–108). Here,
we provide information on the reactive markers that tag specific
microglia/macrophage functions. In addition to the upregula-
tion of constitutive molecules and the expression of polarization
markers, activated microglia/macrophages also express novel anti-
gens associated with specific functions. Reactive antigens include,
among others, CD68, CD200, F4/80, CD14, HLADR, TLRs, heat
shock protein (Hsp)-70, C3b/iC3b, CR3, and sodium calcium
exchanger (NCX)1 (109–114). These markers indicate a reactive
status, but they cannot be used to define whether myeloid cells
have toxic or protective functions. The activation of microglia and
macrophages is linked to different functions, including damage-
sensing activity, chemotaxis, and phagocytosis. These events are
among the most distinctive features of these cells, and specific
markers, discussed below, apply to each reactive phase.
Damage-sensing activity
Microglia are distributed uniformly throughout the CNS. Spe-
cific microglial populations may exist in selective CNS regions
(115), depending on the white or gray matter localization, prox-
imity to vasculature, interaction with BBB components, biochem-
ical features of the microenvironment, and substances released
by neurons (116–118). Functionally, these adaptations guarantee
tissue homeostasis under physiological conditions and are read-
ily activated in case of threats to the CNS. Like macrophages,
microglia are well equipped to sense any change in tissue home-
ostasis thanks to the expression of different surface receptors with
damage-sensing functions. These receptors, generally referred to
as pattern recognition receptors (PRR), bind ligands of differ-
ent types: high mobility group box 1 (HMGB1), Hsp, hyaluronic
acid and fibronectin produced by extracellular matrix degrada-
tion, apoptotic or injured cells, nucleic acids, immune complexes,
mannose residues, and proteolytic enzymes (119). These ligands
are called danger-associated molecular patterns (DAMPs) and are
released as a consequence of insults to the CNS.
Toll-like receptors are a family of PRR that recognize a wide
variety of danger signals and consequently activate different
inflammatory cascades. These receptors, originally identified as
initiators of innate immunity in response to exogenous microor-
ganisms, have a role in the inflammatory response to ischemic
injury in the absence of infection (120). TLRs are expressed by
myeloid cells in response to activation and are involved in the
switch toward M1 polarization (83) either by inducing NF-κB,
which in turn induces pro-inflammatory cytokines (TNFα, IL-12,
SOCS3) and HIF-1α to promote iNOS synthesis, or by inducing
IRF-3, one of the main transcriptional regulators initiating M1
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polarization (via STAT1) and M2 gene silencing (121). TLR4 has
a pivotal role in the promotion of the M1 polarization (83). The
induction of IRF-3 by brief activation of TLR4 or TLR9 can also
have protective effects. Preconditioning with low doses of either
the TLR4 ligand LPS or the TLR9 ligand CpG confers protection
against ischemic injury through IRF-3 and IRF-7, and importantly,
this effect is mediated by glial cells (122).
In the CNS, a few PRR are expressed by other cell types, such
as NOD-like receptor proteins (NLRP) expressed in astrocytes
(NLRP2) or neurons (NLRP1) and the-absent-in-melanoma-2
(AIM2)-like receptor, expressed in neurons. Along with cas-
pases these receptors form the inflammasome and are involved
in pyroptotic events (119). Non-surface-bound PRR exist too.
These include the initiators of the complement cascade, such
as serum proteins C1q, mannose-binding lectin (MBL), ficol-
ins, and collectins, which circulate in the bloodstream and, on
recognition of a wide array of target ligands expressed also by
myeloid cells (123), trigger complement activation leading to
injury progression (124).
Findings in animal models and in humans support the idea that
there is a high degree of interaction between TLRs and comple-
ment. Complement receptors including C5aR, C3aR, and C5L2
crosstalk with TLRs, result in the regulation of innate immune
and inflammatory responses in addition to regulation of adaptive
immunity (125). This interaction may lead to the production of
inflammatory molecules or dampening of excessive inflammation.
The molecular mechanisms leading to this functional regulation
are not completely clear but they include the possibility that com-
plement receptor activation is needed for optimal TLR signaling
or that complement fragments can directly activate TLRs (126).
Crosstalk of complement components with other PRR is also
described. C1q can inhibit NLRP3-dependent cleavage of caspase
3 and subsequent IL-1β cleavage, possibly by increasing the expres-
sion of negative regulators of the inflammasome activity, such as
NLRP12 and/or POP1/ASC2 (127).
The complement system has a major role in the activation
of microglia, cells that constitutively express the receptors for
C1q and for cleavage products of C3, complement components
that mediate phagocytosis and stimulate cytokine production
by microglia. On binding, microglia become activated and in
turn contribute to complement component production that feeds
autocrine/paracrine signaling. Microglia respond to C1q with a
marked shift toward pro-inflammatory activation in CNS diseases
with BBB impairment (128). A role of C1q-mediated activation of
microglia was identified in CNS development, when it is required
to prune neuronal synapses (129). However, C1q influences a mul-
tiplicity of functions associated with macrophages, for instance
upregulating IL-33, a cytokine that can amplify the M2 polar-
ization induced by IL-13 (130, 131). Benoit et al reported that
C1q induced the secretion of anti-inflammatory cytokines, such
as type I interferon, IL-27, and IL-10 by human macrophages
stimulated with low doses of LPS. These effects were abolished
with higher doses of LPS, suggesting that this immunoregulatory
activity occurs with limited inflammatory challenge (127).
There is also evidence suggesting the involvement of MBL, one
of the activators of the lectin complement pathways, in the acti-
vation of microglia. MBL may indirectly induce the activation of
microglia through enhancement of fibrin deposition (53), which
drives microglial recruitment and activation (52).
The purinergic system mediates intimate crosstalk between
microglia and neurons at synapses (132), based on extracellular
ATP/ADP sensing (3). Microglia express P1 receptors – includ-
ing all subclasses of adenosine receptors, e.g., adenosine A1, A2A,
A2B, and A3 receptors (133) – and also P2 receptors, includ-
ing ionotropic P2X (P2X4, P2X7) and metabotropic P2Y (P2Y2,
P2Y4, P2Y6, P2Y12, and P2Y14) receptors (134–136). Microglia
show a certain degree of constitutive expression of these recep-
tors, allowing scanning activity during physiological surveillance.
Surveying microglia express high levels of P2Y12 receptors (137)
that are involved in branch extension. On activation, microglia
can alter their set of purinergic receptors and respond to specific
demands of the surrounding environment. Different purinergic
receptors may be induced simultaneously to obtain coopera-
tive effects, whereas others may function independently or be
silent. For example, microglial activation and reactive transfor-
mation into their ameboid phagocytic phenotype require specific
profiles of purinergic receptors: P2Y12 and A3 receptors cooper-
ate to allow process extension (damage sensing), A2A receptors
induce retraction (ameboid transformation), and P2Y12, P2X4,
and A1 receptors interact to induce migration by ATP/ADP sens-
ing (recruitment to lesion site). Finally, P2Y6 receptors sense UDP
to start phagocytosis (138).
P2Y12 receptors have been proposed as pharmacological targets
(137). As already mentioned, they take part in primary dam-
age sensing through ADP-induced chemotaxis. Early inhibition
of ADP sensing by ticagrelor induces protection from ischemia
at 48 h and is associated with reduced microglia/macrophage
recruitment to the lesion site and with decreased expression of
pro-inflammatory mediators, such as iNOS, IL-1β, and MCP-1
(137). This suggests that microglia have an early toxic effect that
can be counteracted by inhibiting their activation and homing to
the lesion.
Chemotaxis
Following damage-sensing activity,microglia/macrophages become
responsive to chemokines released by the host tissue and pro-
mote the invasion of the inflamed CNS site. The ability of infil-
trating immune cells, such as macrophages, to migrate within
the invaded tissue has long been known by immunologists.
Macrophages abundantly express CC and CXC family surface
receptors for chemokines, among which CCR2 plays a major
role in driving macrophage invasion through monocyte chemoat-
tractant protein 1 (MCP-1) sensing (66–68). Positivity to CCR2
can be exploited in mice to define a specific macrophagic sub-
set, which expresses Ly6C, high levels of Gr1 and low lev-
els of CX3CR1 (139). In humans, the homologous subset is
CCR2high/CD14+/CX3CR1low. Macrophages belonging to this
subset have been associated with the development of the M1
polarization state. A second subset, negative for CCR2, with a
Ly6C-/Gr1low/CX3CR1+ phenotype, has its human homolog in
CCR2low/CD14-/CX3CR1high cells and is associated with the M2
final commitment (139). However, sharp commitment of CCR2
positive or negative subsets is not easily determined because
high levels of its ligand MCP-1 (also known as CCL2) have
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also been described in a M2-polarized inflammatory environ-
ment (140).
Microglia express chemokine receptors of the CC and the
CXC family that, with purinergic receptors, regulate the machin-
ery for microglial movements. In the early metabolic crisis after
acute brain injury, microglia may use chemotactic signals to
extend/withdraw their branches so as to receive activatory stim-
uli and change morphology. Their dynamic proprieties have only
been recently explored, using in vivo imaging by two-photon
microscopy (3, 51). Microglia show constant movements of their
branches to patrol the environment although microglial ability
to displace within the inflamed tissue seems scarce. The fact that
active microglia release a number of factors with paracrine effects
including BDNF (141), IGF-1, and cytokines (142) implies that
they need to reach their site of action. However, their ability to
travel over brain tissue depends on the kind of danger signal
received. In a model of spreading depression in organotypic slice
cultures, causing synaptic activity impairment, microglia showed
displacement by Lévy flight-like movements in response to dimin-
ished synaptic activity (143). In contrast, in models, such as TBI
(induced by laser ablation) (3), photothrombotic stroke, or brain
ischemia (3, 21, 40), microglia did not display any migratory
behavior. Their lack of displacement after acute brain injury may
be related to the rapid decline of ATP levels due to perfusion
impairment, ATP being needed for the cytoskeletal modifications
that microglia exploit for migration (3, 143).
Little is known about microglial dynamics at later times. Pro-
liferating microglia might migrate and settle in specific lesioned
areas where new ones are needed to re-establish tissue homeostasis.
Further studies will help decipher microglia dynamics over time
better, because the literature on this issue so far mainly focuses on
acute points (few hours after insult).
Some markers may be used to detect microglia/macrophages
responding to chemotactic stimuli. F4/80 is commonly used to
stain these cells in tissue. Its expression is enhanced in recruited
tissue macrophages compared to circulating monocytes, indicat-
ing that it is involved in adhesion and tissue migration. Microglia
also express F4/80 at high levels after activation. Interestingly, the
human homolog of F4/80, EMR1, is not present on mononuclear
phagocytic cells, such as macrophages, and in human specimens,
it preferentially stains eosinophils (144).
The NCX1 is involved in the calcium-mediated functions
of microglia, including chemotaxis. Calcium influx through the
action of the exchanger is a prerequisite for bradykinin-induced
microglial motility (145). In a model of brain ischemia, microglia
significantly upregulated NCX1, reaching a peak of expression
3 and 7 days after the insult. NCX1 expression was identi-
fied in round-shaped Iba1+ cells that progressively invaded the
ischemic core. NCX1 knockout mice show impaired chemotaxis
and microglia migration even in the heterozygous state. Impaired
microglia chemotaxis in these mice dramatically increased the
brain ischemic lesion, suggesting that NCX1 is needed to develop
microglial protective functions (110).
Phagocytosis
Phagocytosis is a complex event, whose role in acute brain injury is
still not clear. Phagocytic activity is not clearly linked to a specific
M1 or M2 polarization state. Cells showing M1 toxic as well as M2c
pro-healing polarization may have phagocytic functions (84), indi-
cating that phagocytosis may serve either for killing cells (toxicity)
or scavenging debris (protection).
There is in vitro evidence that M2-polarized cells enhance their
phagocytic behavior (146). This is regarded as a protective func-
tion because phagocytosis is needed for removal of cell debris to
limit the spread of toxic signals and potentially favor tissue healing.
In organotypic slice cultures, microglia may be neuroprotective by
engulfing neutrophils (147).
On the other hand viable neurons exposed to sub-lethal stim-
uli can also express “eat-me” signals that tag them for elim-
ination (148), a process also referred to as primary phago-
cytosis or phagoptosis (149). Two key proteins involved in
the elimination of viable neurons exposing phosphatidylserine
have been identified, namely milk fat globule EGF-like factor-8
(MFG-E8) and Mer receptor tyrosine kinase (MerTK), both of
which bridge phosphatidylserine-exposing neurons to vibronectin
receptors on phagocytic cells (150–153). The fact that the lack
of these proteins prevents neuronal loss and improves behav-
ioral deficits demonstrates the detrimental function of primary
phagocytosis.
In the CNS, myeloid cell phagocytic activity can also be
labeled by CD68, or macrosialin, a scavenger receptor member
of the lysosomal/endosomal-associated membrane glycoprotein
(LAMP) family (8, 109), which is found mainly in phagocytic
macrophages (154). In vivo observations suggest that the expres-
sion of CD68 is inversely related to that of M2 markers during
the temporal evolution of the lesion (8) or in response to protec-
tive manipulations, such as LPS preconditioning (155), stem cell
treatment (140, 156), and CX3CR1 deletion (40).
These observations confirm that the phagocytosis cannot be
ascribed to either M1 or M2 and imply that, although phagocy-
tosis is needed for limiting the propagation of danger signals, any
excess has detrimental effects.
A major effector of phagocytosis is the complement system cas-
cade (124, 157). All the complement activation pathways, includ-
ing those activated by the danger signals released in response to
acute brain injury, converge on the activation of C3 convertase that
leads to C3 cleavage. Its products, C3b/iC3b, are specifically able
to opsonize damaged or apoptotic cells and function as “eat-me”
signals, driving phagocytosis. C3b/iC3b deposits are recognized
by the CD11b/CD18 (or CR3) receptor and may be used to reveal
neurons committed to die.
DOES MORPHOLOGY INDICATE FUNCTION?
Similar to phenotypic markers, morphological changes can pro-
vide information on microglia/macrophage functional commit-
ment. A morphological description is thus a priority to clarify the
specific functional significance of these cells in brain pathology.
The literature has explored the morphology of myeloid cells in
physiological or diseased conditions with the aim of defining spe-
cific shape indicators of a given active/functional state (40, 57,
158). This can be done by combining the morphological data
from imaging with those from conventional molecular analy-
sis – immunostaining, real time PCR, western blots – in different
experimental settings.
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Microglia/macrophage activation is usually measured by
immunohistochemical assessment of the specific antigenic mark-
ers discussed above, but this does not take into consideration
morphological changes and shape descriptors. Actin polymeriza-
tion leading to microglia/macrophage shape changes is strongly
related to ATP/ADP availability and morphological changes are
therefore finely tuned by the injured microenvironment.
Microglia show a wide range of morphological transforma-
tions, from highly ramified with thin branches, to hypertrophic
and ameboid with no branchings. In between these extremes, they
can acquire a variety of shapes that mirror their functional state
[Figure 3 (57)]. Macrophages, in contrast, are less prone to mor-
phological changes. However, a certain amount of shape change is
possible for macrophages too, because due to their plastic nature
they can change their contractility state and establish interactions
with the extracellular matrix and with cell surface adhesion mol-
ecules (159). When macrophages are cultured on substrates that
force their elongation, such as arrays of narrow fibronectin lines,
they start upregulating the M2 markers arginase-1, CD206, and
Ym1 and reduce the release of pro-inflammatory cytokines (160).
The in vitro induction of M2 phenotype by IL-4/IL-13 treatment
causes elongation of the cultured macrophages, indicating that this
is needed to drive the M2 polarization and, more generally, that
geometry plays a role in the phenotype definition (160). Whether
elongation defines polarization in vivo needs investigating because
infiltrating cells may elongate merely as a consequence of crawling
along vessel walls or a perivascular location.
Elongation seems to be an important feature for the defini-
tion of microglial functions as well. The white matter is populated
by a specific microglial subtype, which has a bipolar, elongated
morphology, called rod microglia [Figure 3 (161)]. These cells
are close to neurons (162, 163) and take part in axonal damage
and recovery after injury (118). In other brain areas, elongation
may result as a consequence of directional ramification extending
toward a specific site of injury. This process may be more evident at
early times after injury, being necessary during the damage-sensing
microglia re-orientation. As early as 24 h after ischemic injury,
microglia are not elongated and display a reactive hypertrophic
ameboid morphology with numerous short processes, symmetri-
cally extending from the cell soma (40). This morphological state
correlates with increased lysosomal activity and, interestingly, is
decreased in CX3CR1-deficient mice that show increased expres-
sion of M2 markers and concomitant protection from ischemic
injury (40). A protective role for ramified microglia was sug-
gested by Vinet et al. who showed that these microglia not only
survey their microenvironment but also contribute to protect-
ing neurons during neurodegeneration induced by the glutamate
receptor-agonist N -methyl-d-aspartic acid (158).
The complex morphological features of specific myeloid
populations can be evaluated by measuring different shape
FIGURE 3 | Evolution of myeloid cell morphology and phenotype in the
brain during the acute phases of brain injury. Under physiological
conditions, monocytes, microglia and rod microglia populate specific
compartments, respectively blood, gray matter and white matter. After an
insult to the brain, monocytes, microglia, and rod microglia are activated.
Monocytes migrate to lesioned areas, whereas gray matter microglia are less
likely to displace. Microglia change morphology in a time-dependent fashion,
sprouting new ramifications soon after injury, and then withdrawing branches
to develop an ameboid phenotype. Both infiltrated monocytes and microglia
change their phenotypical profile, acquire specific functional commitments,
and proliferate with time. In the very early phases after injury, microglia have a
M1 phenotype, then, with the recruitment of macrophages, both myeloid
populations upregulate M2 markers. The peak of M2 marker expression soon
vanishes and is followed by upregulation of M1 markers that lasts longer.
In vivo, mixed polarization phenotypes are observed and the M1-M2 definition
may only serve to set the extremes of a continuum of polarization states.
Macrophages from blood-borne monocytes seem to be more able to express
M2 markers than microglia. In the white matter, rod microglia activate after
injury by enhancing their elongated morphology, expressing reactive markers
(CD68, MHCII), and migrating to other areas, such as the hippocampus. Rod
microglia also cluster into trains of cells that align to neuronal axons. Neither
the exact phenotype profile nor the functions of activated rod microglia are
fully understood, though a role of these cells in synaptic stripping due to their
contacts with axons has been hypothesized.
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indices, whose temporal variations are clearly indicative of func-
tional states, providing a quantitative analysis of shape changes
(Figure 4). As an example, the longest branches of surveying
microglia are found within a distance of 20–25 µm from cell cen-
troid when measured by Sholl analysis in vivo in mice (40). One
hour after transient ischemia, the longest branches are found at
30–35 µm from cell centroid indicating ramification sprouting, a
process involved in the sensing of danger signals. Other changes of
myeloid cells after transient ischemia are associated with cell size.
One day after transient ischemia, CD11b+ cells display a mean
cell area of 85.8 µm2, far higher than that in naïve mice (54.6
µm2). Similarly, myeloid cells increase perimeter (75.3 µm) and
cell caliper (20.1 µm) after ischemia compared to controls (61.5
and 17.1 µm, respectively) (41).
Microglial morphology at late times after acute injury or in con-
ditions of chronic activation have been explored little. After TBI,
microglia develop a primed phenotype, defined by increased Iba1
labeling and hypertrophic cell soma that persists up to 30 days after
insult (166). Primed microglia respond to a secondary inflam-
matory challenge with quick activation, yielding depressive-like
behavior.
As amply discussed, microglia modify their shape dynamically
because they can extend or withdraw their branches. While the
number and length of ramifications are indicative of morpho-
logical features associated with microglial function, it is not clear
whether the rate of extension/withdrawal per ramification reveals
a given state. The average speed of extension/retraction (microm-
eters per minute) declines during a vascular occlusion when ATP
is not available, but soon recovers to the baseline values when
new perfusion is allowed (21). This implies that after ischemia the
intrinsic process dynamics of the activated microglia remain unal-
tered. Results are similar with LPS because the process motility
does not change either 2 or 28 days after LPS (167). Hypotheti-
cally microglia may quickly rearrange the length and number of
branches and change morphology without losing their exploratory
ability. However, the residual availability of an energy source is
important for their movements, so environmental changes can
alter microglial exploratory behavior under specific metabolic
circumstances. This point calls for further studies to understand
the dynamic response of microglia during their morphological
transformation.
FUNCTIONAL CONSEQUENCES OF CHRONICALLY ACTIVATED
MICROGLIA
To ensure brain homeostasis, microglia need to finely tune their
physiological activity. The key to this control is the neuron-
mediated inhibitory activity which, under normal conditions,
prevents microglia from becoming active (6). Neurons con-
trol microglia through several components, including contact-
dependent inhibitory signals, such as CD200-CD200R (168),
Hsp60–TREM2–DAP12 (169), CD22-CD45 (170), and CD47-
CD172 (171), and soluble molecules such as ICAM-5 (172),
fractalkine (CX3CL1) (173), IL-10 (174), and TGF-β (175). Any
change in microglial activity control may lead to chronic activa-
tion or a primed state with specific functional consequences. Here,
we discuss three cases in which microglia are chronically activated
and their implications.
CX3CR1-DEFICIENT MICROGLIA ACQUIRE A CHRONIC ACTIVE STATE
CX3CR1, selectively expressed in the brain by microglia, is an
important regulator of their activity. The main effect of CX3CR1
binding to its unique ligand CX3CL1 released by neurons is to con-
trol microglial activation. Under physiological conditions, the neu-
ronal membrane-anchored CX3CL1 is cleaved by the disintegrin-
like metalloproteinases ADAM10 and ADAM17 (176) and is
released in its soluble form. Continuously released CX3CL1 keeps
microglia in a non-reactive state. The generation of cx3cr1GFP/GFP
mice, knockout for CX3CR1 and referred to here as cx3cr1-/- mice,
has led to a number of studies investigating CX3CL1:CX3CR1
signaling either under physiological conditions (177) or in CNS
diseases (178–181), showing the involvement of this pathway in
several aspects of development, homeostasis and injury, including
synaptic pruning, promotion of neuron survival, synaptic trans-
mission and plasticity, enhancement of synaptic networking and
facilitation of neuropathic pain circuits (173).
In cx3cr1-/- mice, the suppressive function of CX3CL1 is pre-
vented and this causes a chronic microglial activation state, with
a larger number of branches than in WT mice, as shown by
FIGURE 4 | Shape changes of different myeloid cell types over time.
Cell size (left panel) can be measured by assessing cell area or cell width
(caliper). While in monocytes (M), the size is constant, microglia (µ) grow
larger (hypertrophic reactive morphology), and rod microglia (rµ) first grow
and then shrink (elongated not ramified morphology). Elongation (center
panel) can be evaluated from the ratio between the cell’s major and minor
axes. A certain degree of elongation is selectively associated with M switch
to M2 polarization. Elongation of µ might occur during early
damage-sensing as µ direct ramifications toward the site of injury. Then,
along with ameboid transformation, µ recover their symmetric shape. In
contrast, rµ progressively elongates so as to align with axons. The rate of
branching (right panel) can be measured by counting the number of
ramifications or by Sholl analysis. M does not have ramifications, while µ or
rµ withdraw branchings over time to acquire, respectively, the ameboid or
the elongated morphology: µ show a transient increase of ramifications
early after injury that may be related to damage-sensing activity. Shape
changes have been plotted according to the data and observations
described in Ref. (40, 118, 160, 161, 164, 165).
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in vivo two-photon microscopy (40). This state has been asso-
ciated with less hippocampal neurogenesis and cognitive deficits
(177, 182, 183).
After an acute insult, such as brain ischemia, affected neurons
significantly reduce the release of CX3CL1, allowing microglial
activation (184, 185). Chronically activated microglia in cx3cr1-/-
mice respond to acute injury by enhancing their ramified mor-
phology, downregulating the phagocytic activity and acquir-
ing features of M2 polarization, together with protection from
ischemic injury (40). There are also reports of early protec-
tive effects of CX3CR1 deletion in different models of acute
brain injury, including ischemia, trauma, or spinal cord injury
(SCI) (179, 181, 186, 187). However, this response may be tran-
sient and at longer times other events may take place, changing
the overall impact of CX3CR1 deficiency. Recruitment of the
CX3CR1+/Ly6Clow/CCR2- macrophage subset has been associ-
ated with beneficial effects as this population is capable of tissue
healing (188). CX3CR1 deficiency would impair the recruitment
of this protective population, resulting in a detrimental phenotype.
The deleterious consequences of CX3CR1 deficiency at late
stages of pathology have been described in ischemia and SCI (189,
190). There is ample literature on cx3cr1-/- mice in chronic CNS
diseases (67). In models of lateral amyotrophic sclerosis (178),
Parkinson’s disease (PS) (191) and Alzheimer’s disease (192),
the absence of CX3CR1 has been associated with a worse out-
come possibly due to the chronic pro-inflammatory function of
CX3CR1-deficient microglia (193, 194).
These findings indicate that specific microglia signaling path-
ways may give opposite outcomes depending on the temporal
pattern of their action or on the disease stage. The longitudi-
nal effects of CX3CR1 deficiency at different stages of pathology
(Table 1) need to be carefully investigated to understand the exact
role of the CX3CL1:CX3CR1 axis in brain injury.
MICROGLIA CHANGE THEIR MORPHOLOGY AND DYNAMICS IN THE
AGING BRAIN
In aged mice (27–28 months), microglia increase their cell soma
volume and shorten mean ramifications. This is accompanied by
quicker soma movements and less baseline process motility than
in young mice [3 months (200)]. Although the morphological fea-
tures of microglia in aging brains are reminiscent of a reactive
state, it is not clear whether the aged microglia are truly activated.
It is likely that these cells enter a dysfunctional state that may affect
the integrity of other structures with which they come into con-
tact, such as neuronal or vascular networks. Possible consequences
of the dysfunctional behavior of aged microglia include dysregu-
lated response to injuries, changes in neuroprotective functions
and increased toxic responses (200).
Table 1 | Effects of CX3CR1 deficiency in different models of CNS diseases.
Model Time from
injury
Deletion
protective?
Effects of deletion Reference
SCI 5–35 days Yes ↑ hindlimb function, ↓ myelin and axon loss, ↑ CD45, ↓ IL-6, and iNOS (181)
42 days No Worsened locomotor function, ↓ myelin, ↑ infiltrating monocytes/macrophages (189)
pMCAo 24 h Yes ↓ ischemic volume (187)
tMCAo 3 days Yes ↓ infarct size (186)
1–3 days Yes ↓ infarct size, ↓BBB breakdown, ↓ apoptosis, ↓microglia, and ↓IL-1β (179)
24 h Yes ↓ infarct size, ↑ ramification in microglia, ↓ CD11b and CD68, ↑ CD45high, ↑Ym1, and
↓iNOS
(40)
72 h Yes ↓ infarct size, ↓ neurological deficit, ↓ apoptosis, ↓ IBA1, and CD45high, ↑Ym1,
↓ iNOS, ↓ microglia proliferation, ↓ ROS, ↓ IL-1, IL-6, and TNF-α
(195)
43–60 days No ↑microglia activation, ↑ IL-1β, andTNF-α, ↓ IL-4 and IL-10, worsens cognitive functions (190)
LPS 4 days No ↑TUNEL, ↑ IL-1β (178)
PD 7 days No ↑ loss Nissl-stained cells, ↑ loss TH-IR (178)
ALS 15–20 weeks No ↓ neuronal cell density, ↓ motor function, ↓ survival (178)
AD 28 days No ↑ IL-6 and TNF-α, ↑Mac2 (activated microglia), ↓ cognitive and memory deficits (192)
28 days Yes ↓ neuronal loss (196)
28 days Yes ↓ Aβ deposition,=CD45, ↓GFAP, ↓TNF-α and MCP-1/CCL2, ↑IL-1b, microglia more
rounded, ↓ CD68, ↑ Aβ phagocytosis
(197)
28 days Yes ↓ Aβ deposition, ↑ Aβ phagocytosis, ↑ microglia proliferation, = neuronal injury (198)
Tau pathology No ↑ MAP phosphorylation, behavioral impairments, ↑ microglial activation, ↑IL-1b (199)
The role of the fractalkine receptor (CX3CR1) in CNS pathologies has been studied using cx3cr1-/- mice. In different disease models, including SCI, permanent ischemia
(pMCAo), transient ischemia (pMCAo), lipopolysaccharide (LPS)-induced inflammation, Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), Alzheimer’s dis-
ease (AD), and Tau pathology. The results are often contrasting and depict a puzzling situation. A potential general hypothesis is that CX3CR1 deletion is protective in
the early phases after acute injury, but becomes deleterious at later stages or in chronic conditions.
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Microglial modifications during aging may be related to
changes in either central or peripheral inflammatory events over
the lifespan. As already discussed, many molecules with paracrine
effect are needed for controlling microglial activation under phys-
iological conditions. However, aging may change the expression
of these molecules, resulting in changes in microglial activation
states. An interesting example of dysregulated microglia control
involves TGFβ1. This cytokine has been defined as a determinant
of microglia support of CNS homeostasis, favoring the microglia
anti-inflammatory phenotype through IRF-7 signaling (71). How-
ever, chronic exposure to TGFβ1 has the opposite effect, inhibiting
IRF-7 and consequently impairing the anti-inflammatory switch
of microglia (201). This latter effect may be important dur-
ing aging because this condition has been reported to induce
chronic TGFβ1 upregulation (202) and can thus cause chronic
pro-inflammatory microglial activation.
As for peripheral inflammatory changes, recent work demon-
strates that mice injected systemically with blood from aged mice
have decreases in neurogenesis, learning, and memory – all effects
mediated by the chemokine system (203). The rules that govern the
interaction between systemic inflammation and microglial behav-
ioral changes throughout life are far from understood. However,
a recent hypothesis attributed to a lifetime peripheral inflamma-
tory state a fundamental role in degenerative pathologies, possibly
through an impact on central inflammation.
The upregulation of MCP-1, a chemoattractant molecule for
myeloid cells, in multiple models of neurodegenerative diseases,
including Alzheimer’s, Parkinson’s, amyotrophic lateral sclerosis,
and prion disease (204–207), has been linked to the possibility
that myeloid cell lineages play a major pathophysiological role. In
chronic disease states, microglia appear to be primed by earlier
pathology or genetic predisposition and respond with hyperacti-
vation to inflammatory stimulation. This might lead to an adaptive
CNS inflammatory response changing into one with deleterious
outcomes (164). Other authors reported a major involvement of
peripheral macrophages rather than microglia in driving chronic
diseased states. In a model of Parkinson’s disease induced by injec-
tion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP),
peripheral M1 macrophages activation proceeds by days microglia
activation and neuronal loss (208). This suggests that, at least
in this model, innate peripheral inflammation is a critical player
rather than a mere consequence.
MICROGLIA IN DEPRESSIVE BEHAVIOR
Individuals who suffered an acute brain injury have a higher inci-
dence of depressive behavior (209). The etiology of increased
depression is still not clear but it may be inflammatory related.
Clinical and experimental data indicate a cause/effect relation-
ship between inflammation and depression (210), which is medi-
ated, at least in part, by high levels of circulating inflammatory
cytokines (211). Experimental studies suggested a strong correla-
tion between the volume of damaged brain tissue and the extent
of systemic immune alterations, irrespective of the site of infarct
(212). Patients with acute brain injury have high levels of circulat-
ing IL-6, and antidepressant therapies fail to reduce TNF-α (211).
These cytokines are released soon after acute brain injuries and
accumulate in cerebrospinal fluid and serum (213–215). Moreover,
markers of neuroinflammation (e.g., CD68, CR3/43) persist in the
brain parenchyma up to 16 years after acute CNS insults (216).
Recent work on experimental models helps attribute a spe-
cific role to microglia in driving neuroinflammation-induced
depressive behavior. Fenn et al. reported that experimental TBI
induces microglia priming that results in a hyperinflammatory
response to an immune challenge, persisting weeks to months
after injury, finally triggering the development of depressive-like
behavior (166).
It is likely that increased microglial sensitivity to secondary
inflammatory challenges (e.g., stressors, infection and injury)
involves mediators of the complement system and PRRs expressed
on the microglial cell surface. However, this has so far been stud-
ied little, and the exact role of primed microglia in late stages after
initial brain insult remains unexplored.
STEM CELL TREATMENT AS A PROOF OF PRINCIPLE OF THE
POSSIBILITY OF DRIVING THE MICROGLIA PHENOTYPE FOR
THERAPEUTIC PURPOSES
Promoting a microglial neuroprotective phenotype is an emerg-
ing therapeutic goal for CNS conditions. One strategy of interest
is the use of stem cells. There is increasing evidence of the effi-
cacy of mesenchymal stromal cells (MSC) in acute brain injury
(217). The paracrine effects of MSC-released bioactive factors
modify the injured microenvironment favoring reparative and
restorative processes. Among the cerebral populations affected
by MSC, microglia are an important target. In vitro and in vivo
evidences show that MSC can tune protective microglial polar-
ization. A direct link between MSC infusion and changes in the
polarization of microglia has been documented in vitro, expos-
ing MSC/microglia co-culture to different toxic stimuli (140, 146,
218). Primary murine microglia co-cultured with MSC increase
the mRNA and protein expression of the M2 markers Ym1 and
CD206 (140). This is obtained when MSC/microglia are co-
cultured in direct contact or in a transwell system, the latter allow-
ing only a paracrine effect. More interestingly, MSC may reverse
the M1 phenotype acquired by microglia after a pro-inflammatory
challenge (by either TNFα+ IL-17 or TNFα+ IFN-γ stimulus),
inducing M2 pro-regenerative traits, as indicated by the down-
regulation of iNOS and upregulation of Ym1 and CD206 mRNA
expression (140). Results are similar after microglia exposure to a
LPS toxic stimulus and MSC co-culture. Again, in control and
inflamed conditions, MSC upregulate mRNA and protein lev-
els of the M2 marker arginase-1 (218) and can to reverse the
microglial M1 phenotype increasing the expression of the M2
marker CD200R (146).
Besides the expression of specific markers, the M2 pheno-
type is associated with a specific profile of released cytokines.
MSC may alter the ratio of IL-10 to TNF-α in favor of the
anti-inflammatory cytokine IL-10 in the supernatants of LPS-
stimulated microglia cultures (218). In addition, the secretome
obtained even with unchallenged MSC reduces the produc-
tion of TNFα, IL-1β, RANTES/CCL5, and MIP-2 by exposed
microglia (219). Interpretation of the microglia cytokine pro-
file after MSC/secretome exposure is not always easy. Rahmat
et al. showed that together with a decrease in the production of
TNF-α, MSC increase the production of IL-6, a cytokine usually
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considered pro-inflammatory (220). Kim and Hematti found a
similar pattern (221) after MSC/macrophage co-culture, reveal-
ing a new CD206+M2 subtype with a IL-10high/IL-12low/IL-6high
phenotype and low secretion of TNF-αlow, potentially implicated
in tissue repair. Increases in MCP-1/CCL2 and IL-1β are reported
in MSC/microglia co-culture (146, 218). MCP-1/CCL2 is a potent
chemoattractant for monocytes and may have a role in tissue repair
and regeneration (222).
Although several aspects of MSC/microglia interaction are not
completely clear yet, there are good reasons to use MSC in vivo as
a driver of microglia post-conditioning after brain injury with the
aim of pushing the M2 protecting phenotype. The first demon-
stration of MSC’s ability to induce in vivo M2 protective mod-
ulation after acute brain injury was provided by Ohtaki et al.
(223) after stroke in mice. After 15 min transient, common carotid
artery occlusion followed by transplantation of 100,000 human
MSC into the dentate gyrus the mice had improved neurological
function and less neuronal cell death in the hippocampus, with
increased protein expression of M2 markers (Ym1, IGF-1, and
Gal-3). Microarray assays indicate that MSC downregulate more
than 10% of the ischemia-induced genes, most of them involved in
inflammatory and immune responses, showing that cell treatment
has a potent immunomodulatory effect. M2 induction after MSC
transplantation has also been seen after SCI (224) or TBI (156),
and in both cases M2 polarization is associated with less scar tissue
formation and improvement of behavioral deficits.
Our group has provided a detailed description of the effects
on microglia/macrophage after MSC infusion in TBI mice, asso-
ciating MSC-induced protection with increased activation of
microglia/macrophages (156). This indicates that MSC in vivo
do not reduce the inflammatory response, but rather pushes it
toward a more protective phenotype. MSC enhance the expres-
sion of M2 markers (Ym1, Arg1, and CD206) over time, making
the M2 phenotype last longer (up to 7 days) than in untreated
animals (3 days). MSC induce general reprograming of the
microenvironment, including increases of IL-10 and VEGF, reduc-
tion of astrogliosis and induction of the axonal regeneration
marker GAP-43. These data indicate that the beneficial traits of
microglia/macrophages induced by MSC skew the balance of the
immune response toward protection and regenerative processes,
further confirming that acting on the microglia/macrophage
modulation would offer therapeutic benefit.
CONCLUSION
Recent evidence has helped define a new role for brain immune
cells, highlighting their involvement in several stages of develop-
ment, homeostasis, aging, or response to injury. Microglia and
macrophages are the main players in neuroinflammation, and
in view of their plastic nature, they may develop either toxic
or protective functions. Specific commitments of these cells are
closely associated with microenvironment signals, including meta-
bolic crisis, exogenous/endogenous danger-associated molecules,
and neuron-mediated activity control. Research in experimental
settings has begun to lay a basis for understanding the behav-
ior of microglia and macrophages in different physiological or
pathological conditions, offering reasons for their therapeutic use.
However, many aspects of their function, e.g., long-term response,
crosstalk with other brain cells, and selective roles of microglia
vs. macrophages, still need to be properly investigated if we are
to acquire the ability to switch neuroinflammation protective
functions.
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